onis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that GSK presented positive end of study data from the Phase 2b B-Clear study of bepirovirsen (formerly IONIS-HBVRx), an investigational antisense oligonucleotide treatment for patients with chronic hepatitis B virus (CHB). The results showed that treatment with bepirovirsen resulted in sustained clearance of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA for 24 weeks after end of bepirovirsen treatment in people with CHB. The study results were presented at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® in Washington, DC.
Signing Day Sports Enters Into Common Stock Purchase Agreement With Tumim Stone Capital LLC To Support Strategic Opportunities And Future Growth Initiatives; No Size Or Amount Disclosed
Signing Day Sports, Inc. ("Signing Day Sports" or the "Company") (NYSE:SGN), the developer of the Signing Day Sports app and platform to aid high school athletes in the recruitment process, today announced that it has
